Tag: CureVac

The chapter for CureVac as an independent publicly traded company has officially closed. The biotech firm's shares have been removed ...

The independent public listing of Tübingen-based mRNA pioneer CureVac has been formally terminated. The company's shares have been delisted from ...

The CureVac share has officially been delisted from public markets, marking the conclusion of its independent trading history. This final ...

The final chapter for Tübingen-based mRNA pioneer CureVac on public markets is now written. A turbulent period in German stock ...

The final chapter has closed for CureVac as a publicly traded entity. The German biotech firm, once a beacon of ...

The independent public trading story for CureVac has reached its conclusion. BioNTech's successful takeover has led to a suspension of ...

The era of CureVac as a publicly traded company has concluded. BioNTech SE has finalized its acquisition of the mRNA ...

A definitive chapter has closed for investors in CureVac. The German biotech firm's standalone history as a publicly traded company ...

The new trading year has begun on a positive note for CureVac, with its shares posting significant gains. This upward ...

The independent journey of CureVac as a publicly traded company has reached its conclusion. The Tübingen-based vaccine developer is now ...